18 reports of this reaction
1.9% of all AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE reports
#10 most reported adverse reaction
ERYTHEMA is the #10 most commonly reported adverse reaction for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, manufactured by Wal-Mart Stores Inc. There are 18 FDA adverse event reports linking AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE to ERYTHEMA. This represents approximately 1.9% of all 931 adverse event reports for this drug.
Patients taking AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE who experience erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ERYTHEMA is a less commonly reported adverse event for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, but still significant enough to appear in the safety profile.
In addition to erythema, the following adverse reactions have been reported for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE:
The following drugs have also been linked to erythema in FDA adverse event reports:
ERYTHEMA has been reported as an adverse event in 18 FDA reports for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ERYTHEMA accounts for approximately 1.9% of all adverse event reports for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, making it a notable side effect.
If you experience erythema while taking AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.